KP TISSUE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.27 CAD | -0.24% |
|
-2.82% | -8.31% |
| Mar. 08 | National Bank Reviews KP Tissue's Q4 Results | MT |
| Mar. 07 | KP Tissue Swings to Profit in Q4; Declares Dividend; Kruger Products' Q4 Profit, Revenue Climbs | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The stock, which is currently worth 2024 to 0.58 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The group shows a rather high level of debt in proportion to its EBITDA.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Personal Products
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.31% | 59.84M | D | ||
| +3.37% | 42.44B | B- | ||
| -15.83% | 3.67B | C+ | ||
| +3.08% | 3.6B | B- | ||
| -0.11% | 2.51B | - | C- | |
| -18.10% | 1.47B | C- | ||
| +21.97% | 1.05B | - | ||
| +11.68% | 885M | - | ||
| +17.55% | 774M | B | ||
| +21.70% | 416M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- KPT Stock
- Ratings KP Tissue Inc.
